Circulating periostin as a potential biomarker to predict platinum-resistant epithelial ovarian cancer.

被引：0
|
作者：
Ryner, Lisa [1 ]
Noyes, Amy [1 ]
Nazzal, Denise [1 ]
Vu, Paul [1 ]
Guan, Yinghui [1 ]
Lu, Shan [1 ]
Morimoto, Alyssa [1 ]
Brignoli, Sue [1 ]
Wang, Yulei [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷
关键词：
D O I：
10.1158/1557-3265.OVCA15-B31
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B31
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Topotecan in platinum-resistant epithelial ovarian cancer
    Karabulut, B
    Sezgin, C
    Terek, MC
    Uslu, R
    Sanli, UA
    Akman, L
    Ozsaran, A
    Dikmen, Y
    Goker, E
    CHEMOTHERAPY, 2005, 51 (06) : 347 - 351
  • [2] PD-1 inhibitor treatment of platinum-resistant epithelial ovarian cancer.
    Oldenburg, Jan
    Normann, Marius
    Turzer, Martin
    Solheim, Olesya
    Diep, Lien My
    Gajdzik, Beata
    Rud, Erik
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Feasibility of bevacizumab combined with gemcitabine in treatment of platinum-resistant epithelial ovarian cancer.
    Kogiku, Ai
    Nagao, Shoji
    Suzuki, Kazuhiro
    Yamamoto, Kasumi
    Senda, Tokihiro
    Kitai, Miho
    Shiozaki, Takaya
    Matsuoka, Kazuko
    Sudo, Tamotsu
    Yamaguchi, Satoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
    Sassu, Carolina Maria
    Palaia, Innocenza
    Boccia, Serena Maria
    Caruso, Giuseppe
    Perniola, Giorgia
    Tomao, Federica
    Di Donato, Violante
    Musella, Angela
    Muzii, Ludovico
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [5] Bevacizumab in patients with advanced platinum-resistant ovarian cancer.
    Cannistra, S. A.
    Matulonis, U.
    Penson, R.
    Wenham, R.
    Armstrong, D.
    Burger, R. A.
    Mackey, H.
    Douglas, J.
    Hambleton, J.
    McGuire, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 257S - 257S
  • [6] Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer
    Porter, Rebecca L.
    Matulonis, Ursula A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (08) : 783 - 796
  • [7] EFFECTIVENESS OF BEVACIZUMAB IN PLATINUM-RESISTANT RECURRENT EPITHELIAL OVARIAN CANCER
    Pinto, R.
    Monteiro, S.
    Lima, B.
    Lopes, A. R.
    Abreu, M.
    Ferreira, M.
    Sousa, S.
    Redondo, P.
    Pereira, D.
    Savva-Bordalo, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A271 - A271
  • [8] Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.
    Michels, Judith
    Ghiringhelli, Francois
    Frenel, Jean-Sebastien
    Brard, Caroline
    You, Benoit
    Floquet, Anne
    Eberst, Lauriane
    Bahleda, Rastilav
    Genestie, Catherine
    Balleyguier, Corinne
    Broutin, Sophie
    Pautier, Patricia
    Colomba, Emeline
    Pommeret, Fanny
    Massard, Christophe
    Marabelle, Aurelien
    Leary, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Paclitaxel in platinum-resistant epithelial ovarian carcinoma
    Wardley, AM
    Jenkins, A
    Alison, DL
    Perren, TJ
    BRITISH JOURNAL OF CANCER, 2000, 83 : 79 - 79
  • [10] Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale
    Kefas, Joanna
    Flynn, Michael
    CANCER DRUG RESISTANCE, 2024, 7
12345